Journal
NATURE CLINICAL PRACTICE ONCOLOGY
Volume 4, Issue 9, Pages 536-550Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/ncponc0905
Keywords
bevacizumab; breast cancer; hypoxia; receptor tyrosine kinase; inhibitor; VeGF
Categories
Funding
- Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline
Ask authors/readers for more resources
Demonstration of the clinically significant activity of bevacizumab in breast cancer has attracted a great deal of interest. Numerous other antiangiogenic treatments are in clinical development and some established therapies including tamoxifen and trastuzumab might function, in part, by suppressing angiogenesis. In this Review, we discuss the potential of various components of the angiogenic pathway as prognostic and predictive factors in breast cancer. In addition, we describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimum use of these agents for the treatment of breast cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available